Nomic Bio GTM brain

category

market profile

• text: Drug discovery and translational researchers need broad protein measurements across many samples, while balancing cost, sensitivity and turnaround.
• text: The high-plex proteomics market includes multiple antibody-based platforms with different coverage, sensitivity and evidence profiles.

personas

• title: Head of high-throughput screening or drug discovery
  pains:

  • Needs protein readouts across large perturbation studies without serial low-plex assays becoming a throughput bottleneck.
  • Must balance assay cost with biological coverage and reproducibility.
• title: Translational biomarker scientist
  pains:

  • Needs quantitative protein profiles from limited and valuable biological samples.
  • Must assess sensitivity, specificity and marker coverage before committing a cohort.
• title: Principal investigator in immunology or oncology
  pains:

  • Wants to identify soluble factors across many samples without building a large profiling operation in-house.
  • Needs help interpreting high-dimensional results.

icp

• text: Pharmaceutical and biotech R&D groups running high-throughput discovery, translational or biomarker studies.
• text: Academic and hospital research groups with substantial sample cohorts and a need for multiplex protein measurements.
• text: Teams planning large perturbation screens or studies where broad panels or custom protein selection improve biological insight.

message pillars

• text: Make high-plex protein profiling accessible at lower cost.
• text: Measure many proteins through a multiplex assay.
• text: Choose panels tailored to the study.
• text: Pair fast service delivery with expert support.

objections

• objection: Will the panel measure the targets and sample matrix we need?
  response: Review the protein library and assay specifications with the team, then validate representative samples before a large study.
• objection: How does the assay compare with our established platform?
  response: Compare sensitivity, coverage, sample requirements and reproducibility on the intended study rather than relying on platform-wide claims.
• objection: Will outsourced profiling fit our timelines?
  response: Agree on sample logistics and turnaround for the specific study; the company advertises turnaround as fast as one week.

competitors

• name: Olink
  why: High-plex protein profiling platform used in discovery and translational studies.
• name: SomaLogic
  why: SomaScan protein profiling is an alternative for broad proteomics studies.
• name: Alamar Biosciences
  why: NULISA multiplex protein assay competes on sensitive biomarker profiling.

influencers

• name: Milad Dagher
  url: https://www.nomic.bio/resources/bridging-the-gaps-in-proteomics
  why: Co-founder and CEO discusses the nELISA platform.

keywords

• high throughput protein profiling
• multiplex proteomics service
• nELISA protein assay
• cytokine profiling large sample cohorts
• drug discovery proteomics
• biomarker protein panel
• Olink alternatives

voice

• scientific and quantitative
• accessibility focused
• confident and research oriented

signals

• text: A pharmaceutical R&D organization is scaling a high-throughput phenotypic or protein biomarker screen.
• text: An academic or clinical research group is assembling a large cohort and seeking protein profiling services.
• text: A research team needs more protein targets per sample or shorter turnaround than its current assays allow.

stack

• nELISA

pricing

motion

channels

• scientific publications
• research partnerships
• events
• SEO

confidence

Founders

• name: Milad Dagher
  title: Founder
  role: Founder
• name: Jeff Munzar
  title: Founder
  role: Founder